Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMed™

Inclusion Criteria: * Women with histologically confirmed AJCC Stage 0-IIIA breast cancer which has been completely surgically resected. * No evidence of disease as determined by their physician. * ER+ and/or PR+ tumour. * Receiving an aromatase inhibitor (letrozole, anastrazole, exemestane) or tamoxifen at a stable dose for at least 3 months at trial entry. * Post-menopausal women, defined as: (1) above 50 years of age who have not menstruated during the preceding 12 months or who have follicle-stimulating hormone levels (FSH) \> 40 IU/L, (2) those under 50 years of age who have FSH hormone levels \>40 IU/L, or (3) those who have undergone a bilateral oophorectomy. * CRP ≥3.9 mg/L measured as the mean of two consecutive weekly tests. * Aged 18 years or older * ECOG performance status 0-1 * Between 2 and 5 years from their initial surgery for breast cancer. * Life expectancy of at least 6 months * At least 6 months since last chemotherapy * Laboratory tests performed within 14 days of trial starting: 1. Granulocytes ≥ 1,500/µL; 2. Platelets ≥ 100,000/µL; 3. Haemoglobin ≥ 12.0 g/dL; 4. Total bilirubin equal to or below upper limit of normal (ULN); 5. AST and ALT equal to or below ULN; 6. Alkaline phosphatase equal to or below ULN; 7. Serum creatinine equal to or below ULN; * Able to provide informed consent to receive the trial treatment, to provide biological specimens, self-administer oral medica-tion unsupervised for a prolonged period of time, and to complete a medication diary. Exclusion Criteria: * Pregnancy or breastfeeding * Who have had a malignancy (other than breast cancer) which required radiotherapy or systemic treatment within the past 5 years. * Known cardiac disease (arrhythmias, myocardial infarction, bundle branch block, ischemic heart disease, uncontrolled hypertension) * Known autoimmune disease or inflammatory disorder * Any condition requiring the use of systemic corticosteroids or any other immunosuppressive agents (e.g. cyclosporin, tacrolimus, azathioprine). * Women with known immunodeficiency (such as HIV). * Patients with infection by septicaemia, infection, acute hepatitis, or other uncontrolled severe medical condition * Routine use of aspirin \>81 mg/d or NSAIDs (\> 400 mg po 4 times/day of ibuprofen or naproxen \> 500 mg/d) or any use of celecoxib or similar COX-2 inhibitors; * Subjects are asked not to take dietary supplements, olives or olive oil for 1 month prior to trial enrolment and during the trial. * Who are taking bisphosphonates